CB-839
Showing 1 - 25 of 245
Leptomeningeal Tumor, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain Trial in United States
Recruiting
- Leptomeningeal Neoplasm
- +6 more
- Sapanisertib
- Telaglenastat Hydrochloride
-
Duarte, California
- +6 more
Dec 29, 2022
Ovarian Cancer, Resistant BRCA Wild-Type Ovarian Cancer Trial in Birmingham (Cohort 1: Dose Escalation, Cohort 2: Dose
Terminated
- Ovarian Cancer
- Resistant BRCA Wild-Type Ovarian Cancer
- Cohort 1: Dose Escalation
- Cohort 2: Dose Escalation
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Apr 29, 2022
Acute Myeloid Leukemia With Multilineage Dysplasia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Blasts 20-30 Percent of
Active, not recruiting
- Acute Myeloid Leukemia With Multilineage Dysplasia
- +6 more
- Azacitidine
- Glutaminase Inhibitor CB-839
-
Houston, TexasM D Anderson Cancer Center
Feb 25, 2022
Solid Tumors, NSCLC, CRC Trial in United States (Telaglenestat (CB-839), Palbociclib Oral Capsule or Tablet [Ibrance])
Completed
- Solid Tumors
- +3 more
- Telaglenestat (CB-839)
- Palbociclib Oral Capsule or Tablet [Ibrance]
-
Santa Monica, California
- +9 more
Sep 14, 2022
Colorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer Trial in Nashville (drug, biological, other,
Recruiting
- Colorectal Cancer
- +3 more
- Glutaminase Inhibitor CB-839
- +5 more
-
Nashville, TennesseeVanderbilt-Ingram Cancer Center
Mar 29, 2022
Colorectal Cancer, Colon Cancer, Rectal Cancer Trial in Cleveland (CB-839, Capecitabine)
Active, not recruiting
- Colorectal Cancer
- +3 more
- CB-839
- Capecitabine
-
Cleveland, Ohio
- +1 more
Jan 14, 2022
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer Trial in United States (CB-839, Talazoparib)
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)
Completed
- Triple Negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
- Paclitaxel
- CB-839
-
Birmingham, Alabama
- +24 more
Sep 19, 2022
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in United
Recruiting
- Advanced Lung Non-Small Cell Carcinoma
- +2 more
- Osimertinib
- Telaglenastat Hydrochloride
-
Birmingham, Alabama
- +10 more
Jan 25, 2023
Prostate Cancer Metastatic Trial in Boston (Telaglenastat, Talazoparib)
Not yet recruiting
- Prostate Cancer Metastatic
-
Boston, MassachusettsMassachusetts General Hospital
Mar 27, 2021
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor
Active, not recruiting
- Advanced Malignant Solid Neoplasm
- +3 more
- Pharmacodynamic Study
- Telaglenastat Hydrochloride
-
Birmingham, Alabama
- +30 more
Sep 1, 2022
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, NSCLC (NSCLC) Trial in United States (CB-839, Nivolumab)
Completed
- Clear Cell Renal Cell Carcinoma (ccRCC)
- +2 more
- CB-839
- Nivolumab
-
Scottsdale, Arizona
- +16 more
Aug 16, 2021
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3 Trial in United States (other, radiation, drug)
Active, not recruiting
- Astrocytoma, IDH-Mutant, Grade 2
- Astrocytoma, IDH-Mutant, Grade 3
- Questionnaire Administration
- +3 more
-
Phoenix, Arizona
- +24 more
Dec 7, 2022
Clear Cell Renal Cell Carcinoma Trial in United States (Placebo, CB-839, everolimus)
Completed
- Clear Cell Renal Cell Carcinoma
- Placebo
- +2 more
-
Tucson, Arizona
- +37 more
Aug 16, 2021
Drug Interaction Trial in Brisbane (Telaglenastat, Famotidine, Placebo for famotidine)
Completed
- Drug Interaction
- Telaglenastat
- +2 more
-
Brisbane, Queensland, AustraliaNucleus Network Brisbane Clinic (formerly Q-Pharm)
Mar 8, 2021
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma Trial in Worldwide (CB-839, Cabozantinib, Placebo)
Completed
- Advanced Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- CB-839
- +2 more
-
Birmingham, Alabama
- +132 more
Aug 18, 2021
NSCLC, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Tumor of Lung Trial in United States (drug,
Terminated
- Non-Small Cell Lung Cancer
- +5 more
- Telaglenastat
- +7 more
-
Birmingham, Alabama
- +101 more
Mar 8, 2022
Childbirth-related Post-traumatic Stress Disorder in
Recruiting
- Post Traumatic Stress Disorder
-
Lausanne, Vaud, SwitzerlandLausanne University Hospital
May 9, 2023
Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM) Trial in United States (CB-839, CB-839 and
Completed
- Non-Hodgkin's Lymphoma (NHL)
- +4 more
- CB-839
- +2 more
-
Scottsdale, Arizona
- +6 more
Jul 16, 2018
Primary Hypertension Trial in Chongqing (External Ultrasonic Micro-bubble)
Not yet recruiting
- Primary Hypertension
- External Ultrasonic Micro-bubble
-
Chongqing, Chongqing, ChinaThe Second Affilated Hospital of Chongqing Medical Universty
Oct 30, 2023
Relapsed/Refractory Multiple Myeloma Trial in New York, Nashville, Salt Lake City (CB-011)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- CB-011
-
New York, New York
- +3 more
Feb 15, 2023
Insomnia Trial in Ann Arbor (Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM), Sleep Hygiene Education (SHE-TM))
Not yet recruiting
- Insomnia
- Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)
- Sleep Hygiene Education (SHE-TM)
-
Ann Arbor, MichiganUniversity of Michigan
Apr 3, 2023
Postoperative Pain, Children, Only Trial in Istanbul (Regional anesthesia intervention)
Completed
- Postoperative Pain
- Children, Only
- Regional anesthesia intervention
-
Istanbul, TurkeyProf. Dr. Cemil Tascioglu City Hospital
Jan 9, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
Caudal Block and Other Methods of Postoperative Pain Relief in
Completed
- Analgesia
- +2 more
- caudal block
- +2 more
-
Manama, BahrainSalmanyia Medical Complex
Oct 10, 2023